دورية أكاديمية
The important role of the histopathologist in clinical trials: challenges and approaches to tackle them.
| العنوان: | The important role of the histopathologist in clinical trials: challenges and approaches to tackle them. |
|---|---|
| المؤلفون: | Provenzano E; Department of Histopathology, Addenbrookes Hospital, Cambridge, UK.; Cambridge NIH Biomedical Research Centre, Cambridge, UK., Driskell OJ; National Institute for Health Research Clinical Research Network West Midlands, Albrighton, UK., O'Connor DJ; Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK., Rodriguez-Justo M; Department Research Pathology, Cancer Institute, University College London, London, UK., McDermott J; Department of Cellular Pathology, University College London Hospital, London, UK., Wong N; Department of Cellular Pathology, Southmead Hospital, Bristol, UK., Kendall T; Centre for Inflammation Research and Edinburgh Pathology, University of Edinburgh, Edinburgh, UK., Zhang YZ; National Centre for Mesothelioma Research, National Heart and Lung Institute, Imperial College London, London, UK.; Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust, London, UK., Robinson M; Centre for Oral Health Research, Newcastle University, Newcastle, UK., Kurian KM; Brain Tumour Research Centre, University of Bristol, Bristol, UK., Pell R; Buckinghamshire Healthcare NHS Trust, Amersham, UK., Shaaban AM; Queen Elizabeth Hospital Birmingham, Birmingham, UK.; University of Birmingham, Birmingham, UK. |
| المصدر: | Histopathology [Histopathology] 2020 Jun; Vol. 76 (7), pp. 942-949. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 7704136 Publication Model: Print Cited Medium: Internet ISSN: 1365-2559 (Electronic) Linking ISSN: 03090167 NLM ISO Abbreviation: Histopathology Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, Blackwell Scientific Publications. |
| مواضيع طبية MeSH: | Clinical Trials as Topic* , Histology* , Pathologists* , Pathology, Clinical*, Humans |
| مستخلص: | High-quality histopathology is essential for the success of clinical trials. Histopathologists have a detailed understanding of tumour biology and mechanisms of disease, as well as practical knowledge of optimal tissue handling and logistical service requirements for study delivery, such as biomarker evaluation, tissue acquisition and turnaround times. As such, histopathologist input is essential throughout every stage of research and clinical trials, from concept development and study design to trial delivery, analysis and dissemination of results. Patient recruitment to trials takes place among all healthcare settings, meaning that histopathologists make an invaluable contribution to clinical trials as part of their routine day-to-day work that often goes unrecognised. More complex evaluation of surgical specimens in the neoadjuvant setting and ever-expanding minimum data sets add to the workload of every histopathologist, not just academic pathologists in tertiary centres. This is occurring against a backdrop of increasing workload pressures and a worldwide shortage of histopathologists and biomedical scientists. Providing essential histopathology support for trials at grassroots level requires funding for adequate resources including histopathologist time, education and training, biomedical scientist and administrative support and greater recognition of the contribution made by histopathology. This paper will discuss the many ways in which histopathologists are involved in clinical trials and the challenges faced in meeting the additional demands posed by trial participation and potential ways to address this, with a special emphasis on the UK model and the Cellular-Molecular Pathology Initiative (CM-Path). (© 2020 John Wiley & Sons Ltd.) |
| References: | Earl H, Provenzano E, Abraham J et al. Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean? BMC Med. 2015; 13; 234. Funt SA, Chapman PB. The role of neoadjuvant trials in drug development for solid tumors. Clin. Cancer Res. 2016; 22; 2323-2328. Russo S, Ammori J, Eads J, Dorth J. The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol. 2016; 12; 669-685. Provenzano E, Bossuyt V, Viale G et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod. Pathol. 2015; 28; 1185-1201. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012; 10; 51. ICH Biomarkers related to Drug or Biotechnology Product Development: Context, Structure and Format of Qualification Submissions. 2010. Available at: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E16/Step4/E16_Step_4.pdf (accessed 25 September 2019). Royal College of Pathologists. Guidance on Inter-Departmental Dispatch of Cellular Pathology Material for Referral and Clinical Trials. 2016. Available at: https://www.rcpath.org/uploads/assets/2ddb60aa-9003-4cd1-9a5a6bbe4d96a324/g137-interdeptdispatch-sep16.pdf (accessed 25 September 2019). Chan A-W, Tetzlaff JM, Altman DG et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann. Intern. Med. 2013; 158; 200-207. Lim SJ. The SPIRIT-Path Extension. 2020. Available at: https://doi.org/10.17605/OSF.IO/E3MF5 (accessed 14 January 2020). Pitman H. SPIRIT-Path. NCRI CMPath. Available at: https://cmpath.ncri.org.uk/our-priorities/spirit-path/ (accessed 14 January 2020). Wilson H, Botfield B, Speirs V. A global view of breast tissue banking. Adv. Exp. Med. Biol. 2015; 864; 69-77. CRUK Pathology Workforce Report. 2016. Available at: https://www.cancerresearchuk.org/sites/default/files/testing_times_to_come_nov_16_cruk.pdf (accessed 23 August 2018). Royal College of Pathologists. Histopathology Workforce Census. 2018. Available at: https://www.rcpath.org/uploads/assets/952a934d-2ec3-48c9-a8e6e00fcdca700f/meeting-pathology-demand-histopathology-workforce-census-2018.pdf (accessed 23 September 2019). Royal College of Pathologists. Staffing Guidelines. 2015. Available at: https://www.rcpath.org/uploads/assets/aaae5525-894f-472c-ae2dfa281829e3d1/g107_guidelinesstaffingworkload_sep15.pdf (accessed 23 August 2018). Rees G, Salto-Tellez M, Lee JL et al. Training and accreditation standards for pathologists undertaking clinical trial work. J. Pathol. Clin. Res. 2019; 5; 100-107. Driskell OJ, Lee JL, Oien KA et al. Pathology and regulation for research in the UK: an overview. F1000Research 2019; 8; 975. Robinson M, James J, Thomas G et al. Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. J. Pathol. Clin. Res. 2019; 5; 91-99. European Society of Pathology. ESP-EORTC collaboration to focus on fellowship and research programs. Available at: https://www.esp-pathology.org/working-groups/esp-research-programs-fellowships/esp-eortc-pathology-research-fellowship-program.html (accessed 8 February 2020). European Commission Medicinal products Clinical Trials Regulation. Available at: https://ec.europa.eu/health/human-use/clinical-trials/regulation_en (accessed 5 May 2020). Pell R, Oien K, Robinson M et al. The use of digital pathology and image analysis in clinical trials. J. Pathol. Clin. Res. 2019; 5; 81-90. Danielsen HE, Hveem TS, Domingo E et al. Prognostic markers for colorectal cancer: estimating ploidy and stroma. Ann. Oncol. 2018; 29; 616-623. Hansen TF, Kjaer-Frifeldt S, Lindebjerg J et al. Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Acta Oncol. 2018; 57; 528-533. Pages F, Mlecnik B, Marliot F et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018; 391; 2128-2139. US Food and Drug Administration. Guidance for Industry Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. Guidance. 2014. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pathologic-complete-response-neoadjuvant-treatment-high-risk-early-stage-breast-cancer-use-endpoint (accessed 23 June 2018). European Medicines Agency. The role of pathological complete response as an endpoint in neoadjuvant breast cancer studies. 2014. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-role-pathological-complete-response-endpoint-neoadjuvant-breast-cancer-studies_en.pdf (accessed 25 September 2019). Provenzano E, Vallier AL, Champ R et al. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-Tango trial. Br. J. Cancer 2013; 108; 866-872. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 2007; 25; 4414-4422. Campbell JI, Yau C, Krass P et al. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res. Treat. 2017; 165; 181-191. Shaaban AM, Purdie CA, Bartlett JM et al. HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice. J. Clin. Pathol. 2014; 67; 161-167. Dodson A, Zabaglo L, Yeo B, Miller K, Smith I, Dowsett M. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study. J. Clin. Pathol. 2016; 69; 128-135. Eddowes PJ, McDonald N, Davies N et al. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Aliment Pharmacol. Ther. 2018; 47; 631-644. McDonald N, Eddowes PJ, Hodson J et al. Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. Sci. Rep. 2018; 8; 9189. |
| معلومات مُعتمدة: | MR/N005872/1 United Kingdom MRC_ Medical Research Council |
| فهرسة مساهمة: | Keywords: clinical trials; education; histopathology; resources |
| تواريخ الأحداث: | Date Created: 20200308 Date Completed: 20210331 Latest Revision: 20240320 |
| رمز التحديث: | 20240320 |
| DOI: | 10.1111/his.14099 |
| PMID: | 32145084 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!